Evidence map›Paper›PMID 32433863›Full record

ArticleACS chemical biology2020

Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.

Erik B Faber, Defeng Tian, David Burban, Nicholas M Levinson, Jon E Hawkinson, Gunda I Georg

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Allosteric regulation and inhibition of protein kinases.Biochemical Society transactions · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Erik B FaberInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-0525-3774
Defeng TianInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-3900-2324
David BurbanDepartment of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-1930-2992
Nicholas M LevinsonDepartment of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-4338-8087
Jon E HawkinsonInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.ORCID 0000-0001-5461-7071
Gunda I GeorgInstitute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-8900-9460
University of Minnesota · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Chemistry-Biology Interface Training GrantT32GM008700 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DISTEFANO, MARK D · 1999 to 2018
$4.0M
Training the Next Generation of Chemical BiologistsT32GM132029 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson, William Charles Krause Pomerantz · 2019 to 2026
$2.7M
Decoding the dynamic mechanism of allosteric activation in the cyclin-dependent kinase Cdk2R01GM121515 · NIGMS · UNIVERSITY OF MINNESOTA · PI LEVINSON, NICHOLAS MARK · 2018 to 2022
$1.5M
Cell-cycle regulatory kinases as targets for male contraceptive drug developmentU01HD080431 · NICHD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI TASH, JOSEPH S · 2014 to 2016
$853k
Allosteric CDK2 inhibitor Discovery and Development for Male ContraceptionR61HD099743 · NICHD · UNIVERSITY OF MINNESOTA · PI CHENNATHUKUZHI, VARGHEESE MANI, GEORG, GUNDA I. · 2019 to 2020
$780k
Development of Allosteric Inhibitors against Cyclin-Dependent Kinase 2 (Cdk2)F30CA232303 · NCI · UNIVERSITY OF MINNESOTA · PI FABER, ERIK · 2019 to 2021
$144k
NCI NIH HHS F30 CA232303NICHD NIH HHS R61 HD099743NICHD NIH HHS U01 HD080431NIGMS NIH HHS R01 GM121515NIGMS NIH HHS T32 GM008244NIGMS NIH HHS T32 GM008700NIGMS NIH HHS T32 GM132029
6 · The paper itself

Abstract

While kinases have been attractive targets to combat many diseases, including cancer, selective kinase inhibition has been challenging, because of the high degree of structural homology in the active site, where many kinase inhibitors bind. We have previously discovered that 8-anilino-1-naphthalene sulfonic acid (ANS) binds an allosteric pocket in cyclin-dependent kinase 2 (Cdk2). Here, we detail the positive cooperativity between ANS and orthosteric Cdk2 inhibitors dinaciclib and roscovitine, which increase the affinity of ANS toward Cdk2 5-fold to 10-fold, and the relatively noncooperative effects of ATP. We observe these effects using a fluorescent binding assay and heteronuclear single quantum correlation nuclear magnetic resonance (HSQC NMR), where we noticed a shift from fast exchange to slow exchange upon ANS titration in the presence of roscovitine but not with an ATP mimic. The discovery of cooperative relationships between orthosteric and allosteric kinase inhibitors could further the development of selective kinase inhibitors in general.

Indexed as

Allosteric RegulationAnilino NaphthalenesulfonatesCyclic N-OxidesCyclin-Dependent Kinase 2Drug SynergismHumansIndolizinesMolecular Docking SimulationProtein BindingProtein Kinase InhibitorsPyridinium CompoundsRoscovitine8-anilino-1-naphthalenesulfonic acidAnilino NaphthalenesulfonatesCyclic N-OxidesCyclin-Dependent Kinase 2dinaciclibIndolizinesProtein Kinase InhibitorsPyridinium CompoundsRoscovitine

Identifiers

PMID32433863
PMCPMC8204636
OpenAlexW3028004189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.